Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2016 Dec 5;7:468. doi: 10.3389/fphar.2016.00468

Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Sabrina C Cecere 1, Sabrina Rossetti 1, Carla Cavaliere 2, Chiara Della Pepa 1, Marilena Di Napoli 1, Anna Crispo 3, Gelsomina Iovane 1, Raffaele Piscitelli 4, Domenico Sorrentino 5, Gennaro Ciliberto 6, Piera Maiolino 4, Paolo Muto 7, Sisto Perdonà 5, Massimiliano Berretta 8, Sandro Pignata 1, Gaetano Facchini 1,*, Carmine D'Aniello 9
PMCID: PMC5136557  PMID: 27924140

In the original article, we have neglected to thank our funder, Novartis Farma S.p.A. The Funding Statement appears below.

Funding

Novartis Farma S.p.A. supported publication of this article.

The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way.

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES